Research snapshot · 7/8/26

ICLRICON

WATCH

Conviction●●●○○3 of 5

Research target$211.13Snapshot target

Thesis statusINTACTLast reviewed 7/8/26

Market cap13.26BSnapshot value

Research history

What changed

Jul 11, 2026

Conviction
1 → 3

Jul 11, 2026

Target
— → $211.13

Jul 11, 2026

Thesis status
NEEDS_MORE_DATA → INTACT

Jul 11, 2026

Last reviewed
Not reviewed → 7/8/26

Jul 8, 2026

Target
— → $211.13

The thesis

Full-service CRO with strong FSP model. Balanced client mix between large pharma (stable) and biotech (growth). Global delivery footprint.

Catalysts

FSP model growth (sponsors building multi-vendor portfolios); biotech funding recovery; global trial footprint expansion; BIOSECURE tailwind.

What breaks it

Funding-cycle beta; pricing pressure in FSP model; client concentration risk; Ireland-domiciled (trades NASDAQ — clean access).

Social sentiment

needs X/Reddit sentiment sweep

Snapshot · 7/8/26

Smart money

🟢 Confirmed · 13F 20+/5- · short↓0.12

Snapshot · 7/8/26